C4X Discovery Holdings Plc Products should attract significant large pharma interest – Zeus Capital

C4X Discovery Holdings Plc (LON:C4XD) is the topic of discussion with Dr Gary Waanders, Healthcare Research Director at Zeus Capital. Gary, runs through the important highlights from the latest results (ending 31st July 2016), how the company has shifted its strategy recently and the benefits this brings and provides an outlook for the company over the coming years.

Dr Clive Dix, CEO of C4X Discovery Holdings Plc, said: “In this period, we taken significant steps towards our vision of becoming the world’s most productive Drug Discovery Engine. We have acquired new technologies to enhance our core target identification and drug design capabilities, expanded our drug asset portfolio and signed new strategic alliances to support our core expertise in solving the drug discovery challenges that confound others. We have defined our strategy to drive revenue through early-stage licensing deals around a high value, pre-clinical portfolio. In the coming year, we will focus on securing deal revenue from our existing portfolio, progressing our discovery candidates to pre-clinical development, identifying novel and exciting drug targets and selectively building our operations to support our vision. I believe C4X Discovery has the team in place to deliver this strategy.”

You might also enjoy reading  Fintel core revenue growth is higher than Zeus forecast

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp